Skin changes by EGFR inhibitors and risk factors for severe acneiform eruption


Epidermal growth factor receptor inhibitors ( EGFRi ), EGFR tyrosine kinase inhibitors ( TKI ) and anti‐EGFR antibodies commonly develop skin toxicities including acneiform eruption.
However, precise skin changes and risk factors for severe acneiform eruption are still unclear.

The objective of a study was elucidation of the useful parameters for early and sensitive detection of the skin changes by EGFRi.

Transepidermal water loss ( TEWL ), skin surface hydration, skin surface lipid levels and erythema / melanin index were serially measured for 2 weeks in 19 EGFR‐TKI Afatinib / Erlotinib‐treated patients and for 8 weeks in 20 anti‐EGFR antibody Cetuximab‐treated patients.

The TEWL levels of the cheek in the patients who developed acneiform eruption of grade 2 and more were already elevated at 7 days after the initiation of Afatinib / Erlotinib therapy compared with those before therapy as well as in patients with grade 1 or less.

In patients treated with Cetuximab, the skin surface hydration on the cheek in acneiform eruption of grade 2 and more patients significantly decreased compared with that of acneiform eruption of grade 1 or less patients at the 2nd and 6th week.

Baseline skin surface lipid levels and erythema index on the cheek of patients with acneiform eruption of grade 2 and more were significantly higher than those with acneiform eruption of grade 1 or less.

The small sample size of the present study, especially for logistic regression analysis, is a limitation.

In conclusion, instrumental evaluation declared rapid inflammatory changes of the skin by EGFR inhibitors and elucidated oily skin as a risk for severe acneiform eruption. ( Xagena )

Source: Journal of Dermatology, 2019

XagenaMedicine_2019



Indietro

Altri articoli

The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...


LUX-Lung 1 was a phase IIb/III study that looked at the benefit of Afatinib ( Giotrif ) and best supportive...


Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung...


EGFR belongs to the ErbB family of transmembrane tyrosine kinase receptors ( ErbB comprises ErbB1/EGFR/HER1, ErbB2/HER2/NEU, ErbB3/HER3, and ErbB4/HER4 )....


A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized...


Improved disease control with continuation of EGFR inhibition beyond progression has been suggested in retrospective / non-randomized studies, however, this...


Afatinib ( Giotrif ) is an oral, irreversible ErbB family blocker of EGFR, HER2, ErbB3 and ErbB4 signalling. LUX-Lung 3...


New results from a retrospective study suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin...


Results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab...